MetaCap

Agios Pharmaceuticals (AGIO) vs First Tracks Biotherapeutics (TRAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

First Tracks Biotherapeutics is the larger company by market cap ($1.75 billion vs $1.65 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO-20.69%TRAX+119.16%
+186%+73%-40%
Apr 6, 20261 yearNov 20, 2026
AGIO-16.16%TRAX+77.19%
+111%+36%-39%
Apr 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus TRAX key metrics
MetricAGIOTRAX
Share price$27.60$41.64
Market cap$1.65B$1.75B
1-day change-4.03%-6.34%
YTD return+1.40%—
1-year return+9.35%—
5-year return-24.28%—
EPS (TTM)$-6.31$-4.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M—
Revenue growth (YoY)+48.03%—
Net income (latest FY)$-412.78M—
Gross margin88.26%—
Operating margin-873.87%—
Net margin-764.01%—
52-week high$44.09$54.78
52-week low$24.16$14.72
Distance from 52-week high-37.40%-23.99%
Analyst consensusbuystrong_buy
Avg. price target upside+67.07%+80.52%
Average volume1.06M826.70K
Shares outstanding59.81M42.02M
Employees539104
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About First Tracks Biotherapeutics

TRAX stock →

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees

AGIO vs TRAX FAQ

Which is bigger, Agios Pharmaceuticals or First Tracks Biotherapeutics?

First Tracks Biotherapeutics (TRAX) is larger, with a market capitalization of $1.75B compared with $1.65B for Agios Pharmaceuticals (AGIO).

Are Agios Pharmaceuticals and First Tracks Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons